ViiV Healthcare
Subsidiary of GlaxoSmithKline (GSK)
Assets
(10 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | HIV integraseSmall molecule | HIV | |
| Approved | HIV integrase · HIV reverse transcriptaseSmall molecule | HIV | |
Dolutegravir(Tivicay / Triumeq / Dovato / Juluca (component)) | Approved | HIV integraseSmall molecule | HIV |
Fostemsavir(Rukobia) | Approved | HIV gp120Small molecule | HIV |
Maraviroc(Selzentry / Celsentri) | Approved | CCR5 co-receptorSmall molecule | HIV |
| Phase 2 | HIV capsidSmall molecule | HIV | |
| Phase 2 | HIV envelopeMonoclonal antibody | HIV | |
| Phase 2 | HIV capsidSmall molecule | HIV | |
| Phase 2 | HIV integraseSmall molecule | HIV | |
| Phase 1 | Undisclosed / early pipelineSmall molecule | HIV |
Discontinued programmes (3)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
2029 (3)
2032 (2)
June 2032 (1)
What to watch
September 2032 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.